Targets of axitinib

The main targets of axitinib are receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR) and c-KIT on the surface of tumor cells. These receptors play key roles in cell signaling and angiogenesis. By inhibiting these receptors, axitinib can affect angiogenesis, inhibit the growth and spread of tumor cells, and thus have a therapeutic effect on cancers such as advanced renal cell carcinoma. The targeted nature of axitinib makes it an effective targeted therapy, providing a targeted treatment strategy for cancer patients, while also requiring close monitoring of patient response and possible side effects during use.